Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Holding HRTX?
Track your performance easily
HRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.04 - $3.93
Previous Close$1.07
Volume1.46M
Average Volume (3M)1.83M
Market Cap
$162.74M
Enterprise Value$270.10M
Total Cash (Recent Filing)$70.89M
Total Debt (Recent Filing)$178.25M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Feb 20, 2025EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding152,094,912
10 Day Avg. Volume2,762,833
30 Day Avg. Volume1,827,473
Standard Deviation0.27
R-Squared0.12
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-4.31
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)13.40
P/FCF Ratio15.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.96
Enterprise Value/Gross Profit4.36
Enterprise Value/Ebitda-13.34
Forecast
1Y Price Target
$6.50Price Target Upside467.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Heron Therapeutics News
PremiumCompany Announcements
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance
PremiumCompany Announcements
Heron Therapeutics Strengthens Leadership with New Board AppointmentBulls Say, Bears Say
Bulls Say
Financial PerformanceHRTX is confident in a significant bounce-back with 4Q sales of $37MM-$43MM and positive adjusted EBITDA.
Market StrategyThe improved product presentation along with the broad label expansion in January and the ongoing deployment of the CrossLink partnership are all expected to help the product's uptake ahead of the NOPAIN Act implementation in 2025.
Product DevelopmentFDA approved HRTX's application for a new product presentation of Zynrelef that includes a vial access needle (VAN).
Bears Say
EarningsHRTX reported a top-line revenue of $32.8 million, which significantly missed the Street's expectation of $36.8 million.
Product PerformanceThe CINV franchise, particularly Cinvanti, showed a decline attributed to quarterly fluctuations, leading to investor disappointment.
Profitability ConcernsInvestor focus remains on HRTX's quarterly numbers and progress towards profitability, following a previous slight miss on top-line earnings.
---
Ownership Overview
5.20% Insiders
11.70% Mutual Funds
44.37% Other Institutional Investors
29.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRTX FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $1.04 and its highest was $3.93 in the past 12 months.
What is Heron Therapeutics’s market cap?
Currently, no data Available
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 86 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.008.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -$0.03.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 152,094,910 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went down -30.435%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Among the largest hedge funds holding Heron Therapeutics’s share is EntryPoint Capital, LLC. It holds Heron Therapeutics’s shares valued at 30K.
---
Heron Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (467.69% Upside)
$6.50 (467.69% Upside)
Blogger Sentiment
Bullish
HRTX Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 221.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
---
HRTX Company Deck
---
HRTX Earnings Call
Q3 2024
0:00 / 0:00
---
HRTX Stock 12 Month Forecast
Average Price Target
$6.50
▲(467.69% Upside)
Technical Analysis
Best Analysts Covering HRTX
1 Year
1 Year Success Rate
5/32 ratings generated profit
1 Year Average Return
-35.32%
reiterated a buy rating 14 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 15.63% of your transactions generating a profit, with an average return of -35.32% per trade.
---